MaxCyte Inc - Maryland-based cell and gene therapies firm - Revenue in half year ended June 30 down 30% to USD10.9 million from USD8.4 million. Net loss narrows to USD6.1 million from USD9.5 million. "Our full-year 2020 revenue outlook has improved from the initial uncertainty outlined in April, although the ongoing Covid pandemic still limits visibility," Chief Executive Officer Doug Doerfler says.
Current stock price: 354.00 pence
Year-to-date change: up sharply from 125.00p on December 31
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
MaxCyte (MXCT)